Skip to main content

Table 1 Clinical characteristics and ongoing treatment of 72 SLE patients

From: Serum S100A8/A9 concentrations are associated with neuropsychiatric involvement in systemic lupus erythematosus: a cross-sectional study

Clinical characteristics

 

Age at study, median (range), years

38 (18–52)

Disease duration, median (range), years

10 (0–32)

SLICC/ACR-Damage Index, median (range)

0 (0–5)

SLEDAI-2 K, median (range)

2 (0–18)

SLICC classification criteria

 

Acute cutaneous lupus, n (%)

53 (74%)

Chronic cutaneous lupus, n (%)

18 (25%)

Oral or nasal ulcers, n (%)

31 (43%)

Nonscarring alopecia, n (%)

24 (33%)

Joint disease, n (%)

62 (86%)

Serositis, n (%)

29 (40%)

Renal manifestations, n (%)

29 (40%)

Neurologic manifestations, n (%)

13 (18%)

Haemolytic anaemia, n (%)

4 (6%)

Leukopenia/lymphopenia, n (%)

42 (58%)

Thrombocytopenia, n (%)

20 (28%)

ANA, n (%)

71 (99%)

Anti-dsDNA, n (%)

44 (61%)

Anti-Sm, n (%)

11 (15%)

Anti-PL, n (%)

24 (33%)

Low complement, n (%)

43 (60%)

Positive Direct Coombs test, n (%)

2 (3%)

Medication, ongoing

 

Cyclophosphamide, n (%)

1 (1%)

Azathioprine, n (%)

23 (32%)

Mycophenolate, n (%)

16 (22%)

Rituximab, n (%)

1 (1%)

Methotrexate, n (%)

1 (1%)

Belimumab, n (%)

8 (11%)

Hydroxychloroquine, n (%)

57 (79%)

Any DMARD except hydroxychloroquine, n (%)

43 (60%)

Intravenous immunoglobulin, n (%)

2 (3%)

Prednisolone, n (%)

57 (79%)

Prednisolone daily dose, median (range), mg/day

5 (0–25)

  1. SLICC: Systemic lupus erythematosus international collaborating clinics. ACR: american college of rheumatology. SLEDAI-2 K: SLE disease activity Index 2000. ANA: Antinuclear antibody. Anti-dsDNA: anti-double stranded DNA. Anti-Sm: anti-smith. Anti-PL: anti-phospholipid antibody. DMARD: disease-modifying antirheumatic drug